Evidence map›Paper›PMID 41245892›Full record

ArticleComputational and structural biotechnology journal2025

Predicting PROTAC off-target effects via warhead involvement levels in drug-target interactions using graph attention neural networks.

Yutong Hu, Kieran Didi, Adam P Cribbs, Jianfeng Sun

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization.Computational and structural biotechnology journal · 2026
    Article
  2. Pharmacological modulation of stress granulesFrontiers in pharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yutong HuThrust of Bioscience and Biomedical Engineering, Hong Kong University of Science and Technology (Guangzhou), Guangzhou 511400, China.
Kieran DidiDepartment of Computer Science, University of Oxford, Oxford OX1 3QG, UK.
Adam P CribbsBotnar Research Centre, University of Oxford, Oxford OX3 7LD, UK.
Jianfeng SunThrust of Bioscience and Biomedical Engineering, Hong Kong University of Science and Technology (Guangzhou), Guangzhou 511400, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteolysis-targeting chimeras (PROTACs) represent an emerging modality for targeted protein degradation with broad therapeutic potential. However, the risk of off-target protein degradation remains a major concern in the development of PROTAC-based therapeutics. Here, we present SENTINEL, a graph-based deep learning framework that predicts the off-target propensity of PROTAC warheads based on their involvement levels in drug-target interactions as determined from established databases and the literature. By encoding warheads as molecular graphs using path-augmented graph transformer networks (PAGTNs), we show that graph attention-based neural networks (GATs) achieve accurate modelling of binding count-based off-target effects with an area under the ROC curve (AUC) of 0.9600 and an F1-score of 0.6983, outperforming classical machine learning algorithms such as random forests (AUC=0.840, F1-score=0.2778). SENTINEL provides a scalable strategy to prioritise lower-risk warheads in a low-data setting, supporting early-stage evaluation of PROTAC off-target risk. Results should be interpreted with the dataset size in mind and will benefit from larger external validation.

Indexed as

Deep learningDegradationGraph attention networksOff-target effectsPROTACs

Identifiers

PMID41245892
PMCPMC12613028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.